Loading
SERENA-6 showed you can act on a blood test before the scan changes. The same logic could apply to PIK3CA, AKT1, or HER2 mutations emerging on treatment.
This idea generalises SERENA-6: run serial ctDNA during first-line aromatase inhibitor plus CDK4/6 therapy for HR-positive breast cancer and, when a PIK3CA or AKT1 mutation emerges, add capivasertib or inavolisib before the scan changes, with T-DXd the analogous move for HER2 activation. Resistant clones are smaller and less heterogeneous at molecular than at radiographic progression, and SERENA-6 showed that acting at this earlier point lengthens disease control. The test is a platform trial randomising at mutation emergence to an immediate pathway-matched drug versus continuation, with PFS2 as primary endpoint and patient-reported outcomes to answer the ODAC critique. At an early clinical stage, it addresses the tumour-heterogeneity and acquired-resistance bottlenecks.
After bladder removal, a blood test can now tell who needs immunotherapy and who can safely be spared it. This is the model for MRD-guided adjuvant therapy across cancers: treat the blood-positive, watch the blood-negative.
One of the most cited reviews Europe PMC returns for Capivasertib in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Capivasertib in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Capivasertib in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares ESR1 mutation, SERENA-6, Camizestrant, HR-positive / HER2-negative breast cancer.
Shares SERENA-6, Camizestrant, Capivasertib, Liquid biopsy (ctDNA).
Shares "The emerging role of capivasertib in breast cancer", HR-positive / HER2-negative breast cancer.
Shares ESR1 mutation, Camizestrant, Circulating tumour DNA (ctDNA), HR-positive / HER2-negative breast cancer.
Shares A clone report from blood at every treatment cycle, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
Shares Inavolisib, Capivasertib, HR-positive / HER2-negative breast cancer.
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).